Latest Articles
EndoDiagnosis Announces CReATe Fertility as First Canadian Clinic to Offer Tier 1 ENDOSURE Diagnostic Test for Endometriosis - Akron Beacon Journal
EndoDiagnosis Announces CReATe Fertility as First Canadian Clinic to Offer Tier 1 ENDOSURE Diagnostic Test for Endometriosis Akron Beacon Journal
Published: Nov. 25, 2025, 5:16 p.m.
Proteomics International Secures Grant for Endometriosis Diagnostic Test - MSN
Proteomics International Secures Grant for Endometriosis Diagnostic Test MSN
Published: Nov. 25, 2025, 2:30 p.m.
EndoDiagnosis Announces CReATe Fertility as First Canadian Clinic to Offer Tier 1 ENDOSURE Diagnostic Test for Endometriosis - Markets Financial Content
EndoDiagnosis Announces CReATe Fertility as First Canadian Clinic to Offer Tier 1 ENDOSURE Diagnostic Test for Endometriosis Markets Financial Content
Published: Nov. 25, 2025, 12:42 a.m.
Acute Hemoperitoneum Secondary to Chronic Hematosalpinx: A Diagnostic Challenge in the Setting of a Negative Pregnancy Test - Cureus
Acute Hemoperitoneum Secondary to Chronic Hematosalpinx: A Diagnostic Challenge in the Setting of a Negative Pregnancy Test Cureus
Published: Nov. 20, 2025, 3:17 p.m.
PIQ: Commercial ramp-up of four novel diagnostic tests targets major US and Australian markets - TradingView
PIQ: Commercial ramp-up of four novel diagnostic tests targets major US and Australian markets TradingView
Published: Nov. 20, 2025, 3:50 a.m.
An assisted diagnostic and prognostic model for endometrial cancer using 36 serological markers and clinical variables from 562 patients - Nature
An assisted diagnostic and prognostic model for endometrial cancer using 36 serological markers and clinical variables from 562 patients Nature
Published: Nov. 18, 2025, 2:28 p.m.
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer - Fierce Biotech
Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer Fierce Biotech
Published: Nov. 13, 2025, 9 a.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare
Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어
Published: Nov. 13, 2025, 5:50 a.m.
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer - CancerNetwork
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer CancerNetwork
Published: Nov. 12, 2025, 7:12 p.m.
Link copied to clipboard!